Data from the CANTOS trial showed that neutralizing IL‐1β, a prominent SASP member (Malaquin et al. 2016), with canakinumab benefited patients with coronary artery disease (CAD) (Ridker et al. 2017, 2018). This evidence concerns the gene IL1B and coronary artery disorder.